The estimated Net Worth of Kevin Joseph Fitzgerald is at least $9.62 Milión dollars as of 12 August 2024. Kevin Fitzgerald owns over 22,025 units of Alnylam Pharmaceuticals Inc stock worth over $3,373,663 and over the last 3 years he sold ALNY stock worth over $6,245,281. In addition, he makes $0 as Senior Vice President a Chief Scientific Officer at Alnylam Pharmaceuticals Inc.
Kevin has made over 2 trades of the Alnylam Pharmaceuticals Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 22,025 units of ALNY stock worth $5,968,555 on 12 August 2024.
The largest trade he's ever made was selling 22,025 units of Alnylam Pharmaceuticals Inc stock on 12 August 2024 worth over $5,968,555. On average, Kevin trades about 3,871 units every 8 days since 2021. As of 12 August 2024 he still owns at least 12,881 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of Kevin Fitzgerald stock trades at the bottom of the page.
Dr. Kevin Fitzgerald is Senior Vice President, Chief Scientific Officer of the company. Dr. Fitzgerald will be responsible for the strategic direction and oversight of Alnylam's discovery engine. He has over 20 years of experience in the context of small molecule and oligonucleotide drug discovery. Dr. Fitzgerald's tenure at Alnylam began in 2005 when he joined as an Associate Director of Research. He has headed the Research department since 2016. His achievements include leadership of Alnylam's RNAi delivery efforts, resulting in two clinically validated modes of siRNA delivery, as well as the development of the Company's comprehensive clinical pipeline. He is an inventor on over 50 patents that apply to the majority of Alnylam's pipeline programs, and the author of over 40 manuscripts, including many in prestigious journals such as Nature, Cell , and The New England Journal of Medicine . Kevin has led or supported multiple programs from discovery through various stages of clinical development. Kevin received his Bachelor of Science in Genetics from Cornell University and his doctorate in Molecular Biology from Princeton University. He completed his post-doctoral fellowship at Harvard Medical School.
Kevin's mailing address filed with the SEC is 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142.
Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal a Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: